Volume 21, Issue 1 - Medical Writing in Oncology

Journal Watch

Authors: Nancy Milligan, Stephen Gilliver

Abstract

Download the full article

References

1. Getz KA, Zuckerman R, Cropp AB, Hindle AL, Krauss R, Kaitin KI. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Inf J 2011;45(03):265–75.
2. Del Parigi A. Industry funded clinical trials: bias and quality. Curr Med Res Opin 2012;28(1):1–3.
3. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003;290(7):921–8.
4. Thomas O, Thabane L, Douketis J, Chu R, Westfall AO, Allison DB. Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond) 2008;32(10):1531–6.
5. Golder S, Loke YK. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol 2008;66(6):767–73.
6. Shaw D. The ICMJE's definition of authorship is illogical and unethical. BMJ 2011;343:bmj.d7192.
7. Lippert S, Callaham ML, Lo B. Perceptions of conflict of interest disclosures among peer reviewers. PLoS One 2011;6(11):e26900.
8. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. [cited 30 November 2011]. Available from: http://www.icmje.org/urm_full.pdf
9. Callaham ML. Journal policy on ethics in scientific publication. Ann Emerg Med 2003;41(1):82–9.
10. Annals of Emergency Medicine. Annals conflict of interest policy for editors and reviewers. [cited 1 December 2011]. Available from: http://www.annemergmed.com/content/instauth#conflict
11. Isaacs D. Conflict of interest: no such thing as a free lunch. J Paediatr Child Health 2011;47(10):679–80.